Brand-Name, Generics Deals Stifle Competition: FTC
Patent settlements in which drugmakers pay their generics rivals to keep generic competition off the market may stifle competition, according to a report from the U.S. Federal Trade Commission released on...To view the full article, register now.
Already a subscriber? Click here to view full article